Can t(8;21) oligoblastic leukemia be called a myelodysplastic syndrome?

Kinuyo Kaneda, Kensuke Kojima, Makoto Takeuchi, Hidetaka Takimoto, Seiji Takaba, Katsuji Shinagawa, Hajime Kobayashi, Akira Miyata, Masamichi Hara, Mitsune Tanimoto

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

The new World Health Organization (WHO) classification of hematologic malignancies has incorporated t(8;21) myelodysplastic syndromes (MDS) according to the French-American-British classification into the category of acute myeloid leukemia (AML) with t(8;21)(q22;q22), while our knowledge about clinicopathological features of t(8;21) oligoblastic leukemia is still limited. We present our experience with 12 patients meeting the FAB diagnostic criteria of MDS and having t(8;21), who were compared to 43 t(8;21) AML patients. The MDS and AML patients shared most hematomorphologic, immunophenotypic, and clinical features, whereas the differences lay along myeloid maturation. The MDS patients had higher percentages of circulating neutrophils and marrow myeloid cells beyond promyelocytes than the AML patients. The incidence of Auer rods in mature neutrophils in MDS was significantly higher than that in AML, and furthermore, the neutrophils in MDS more commonly contain t(8;21) than in AML. Our findings support the rationale for the WHO classification, and future studies on large patient populations should help clarify whether the spontaneous differentiation potential could be actively associated with a hematological manifestation of t(8;21) leukemias.

Original languageEnglish
Pages (from-to)165-170
Number of pages6
JournalEuropean Journal of Haematology
Volume69
Issue number3
DOIs
Publication statusPublished - Sep 1 2002

Fingerprint

Myelodysplastic Syndromes
Acute Myeloid Leukemia
Leukemia
Neutrophils
Granulocyte Precursor Cells
Hematologic Neoplasms
Myeloid Cells
Bone Marrow
Incidence
Population

Keywords

  • Acute myeloid leukemia
  • Fluorescence in situ hybridization analysis
  • Myelodysplastic syndrome
  • Oligoblastic leukemia
  • Translocation (8;21)

ASJC Scopus subject areas

  • Hematology

Cite this

Kaneda, K., Kojima, K., Takeuchi, M., Takimoto, H., Takaba, S., Shinagawa, K., ... Tanimoto, M. (2002). Can t(8;21) oligoblastic leukemia be called a myelodysplastic syndrome? European Journal of Haematology, 69(3), 165-170. https://doi.org/10.1034/j.1600-0609.2002.02770.x

Can t(8;21) oligoblastic leukemia be called a myelodysplastic syndrome? / Kaneda, Kinuyo; Kojima, Kensuke; Takeuchi, Makoto; Takimoto, Hidetaka; Takaba, Seiji; Shinagawa, Katsuji; Kobayashi, Hajime; Miyata, Akira; Hara, Masamichi; Tanimoto, Mitsune.

In: European Journal of Haematology, Vol. 69, No. 3, 01.09.2002, p. 165-170.

Research output: Contribution to journalArticle

Kaneda, K, Kojima, K, Takeuchi, M, Takimoto, H, Takaba, S, Shinagawa, K, Kobayashi, H, Miyata, A, Hara, M & Tanimoto, M 2002, 'Can t(8;21) oligoblastic leukemia be called a myelodysplastic syndrome?', European Journal of Haematology, vol. 69, no. 3, pp. 165-170. https://doi.org/10.1034/j.1600-0609.2002.02770.x
Kaneda K, Kojima K, Takeuchi M, Takimoto H, Takaba S, Shinagawa K et al. Can t(8;21) oligoblastic leukemia be called a myelodysplastic syndrome? European Journal of Haematology. 2002 Sep 1;69(3):165-170. https://doi.org/10.1034/j.1600-0609.2002.02770.x
Kaneda, Kinuyo ; Kojima, Kensuke ; Takeuchi, Makoto ; Takimoto, Hidetaka ; Takaba, Seiji ; Shinagawa, Katsuji ; Kobayashi, Hajime ; Miyata, Akira ; Hara, Masamichi ; Tanimoto, Mitsune. / Can t(8;21) oligoblastic leukemia be called a myelodysplastic syndrome?. In: European Journal of Haematology. 2002 ; Vol. 69, No. 3. pp. 165-170.
@article{d7c1a6d973fd407682ab9571fa726795,
title = "Can t(8;21) oligoblastic leukemia be called a myelodysplastic syndrome?",
abstract = "The new World Health Organization (WHO) classification of hematologic malignancies has incorporated t(8;21) myelodysplastic syndromes (MDS) according to the French-American-British classification into the category of acute myeloid leukemia (AML) with t(8;21)(q22;q22), while our knowledge about clinicopathological features of t(8;21) oligoblastic leukemia is still limited. We present our experience with 12 patients meeting the FAB diagnostic criteria of MDS and having t(8;21), who were compared to 43 t(8;21) AML patients. The MDS and AML patients shared most hematomorphologic, immunophenotypic, and clinical features, whereas the differences lay along myeloid maturation. The MDS patients had higher percentages of circulating neutrophils and marrow myeloid cells beyond promyelocytes than the AML patients. The incidence of Auer rods in mature neutrophils in MDS was significantly higher than that in AML, and furthermore, the neutrophils in MDS more commonly contain t(8;21) than in AML. Our findings support the rationale for the WHO classification, and future studies on large patient populations should help clarify whether the spontaneous differentiation potential could be actively associated with a hematological manifestation of t(8;21) leukemias.",
keywords = "Acute myeloid leukemia, Fluorescence in situ hybridization analysis, Myelodysplastic syndrome, Oligoblastic leukemia, Translocation (8;21)",
author = "Kinuyo Kaneda and Kensuke Kojima and Makoto Takeuchi and Hidetaka Takimoto and Seiji Takaba and Katsuji Shinagawa and Hajime Kobayashi and Akira Miyata and Masamichi Hara and Mitsune Tanimoto",
year = "2002",
month = "9",
day = "1",
doi = "10.1034/j.1600-0609.2002.02770.x",
language = "English",
volume = "69",
pages = "165--170",
journal = "European Journal of Haematology",
issn = "0902-4441",
publisher = "Wiley-Blackwell",
number = "3",

}

TY - JOUR

T1 - Can t(8;21) oligoblastic leukemia be called a myelodysplastic syndrome?

AU - Kaneda, Kinuyo

AU - Kojima, Kensuke

AU - Takeuchi, Makoto

AU - Takimoto, Hidetaka

AU - Takaba, Seiji

AU - Shinagawa, Katsuji

AU - Kobayashi, Hajime

AU - Miyata, Akira

AU - Hara, Masamichi

AU - Tanimoto, Mitsune

PY - 2002/9/1

Y1 - 2002/9/1

N2 - The new World Health Organization (WHO) classification of hematologic malignancies has incorporated t(8;21) myelodysplastic syndromes (MDS) according to the French-American-British classification into the category of acute myeloid leukemia (AML) with t(8;21)(q22;q22), while our knowledge about clinicopathological features of t(8;21) oligoblastic leukemia is still limited. We present our experience with 12 patients meeting the FAB diagnostic criteria of MDS and having t(8;21), who were compared to 43 t(8;21) AML patients. The MDS and AML patients shared most hematomorphologic, immunophenotypic, and clinical features, whereas the differences lay along myeloid maturation. The MDS patients had higher percentages of circulating neutrophils and marrow myeloid cells beyond promyelocytes than the AML patients. The incidence of Auer rods in mature neutrophils in MDS was significantly higher than that in AML, and furthermore, the neutrophils in MDS more commonly contain t(8;21) than in AML. Our findings support the rationale for the WHO classification, and future studies on large patient populations should help clarify whether the spontaneous differentiation potential could be actively associated with a hematological manifestation of t(8;21) leukemias.

AB - The new World Health Organization (WHO) classification of hematologic malignancies has incorporated t(8;21) myelodysplastic syndromes (MDS) according to the French-American-British classification into the category of acute myeloid leukemia (AML) with t(8;21)(q22;q22), while our knowledge about clinicopathological features of t(8;21) oligoblastic leukemia is still limited. We present our experience with 12 patients meeting the FAB diagnostic criteria of MDS and having t(8;21), who were compared to 43 t(8;21) AML patients. The MDS and AML patients shared most hematomorphologic, immunophenotypic, and clinical features, whereas the differences lay along myeloid maturation. The MDS patients had higher percentages of circulating neutrophils and marrow myeloid cells beyond promyelocytes than the AML patients. The incidence of Auer rods in mature neutrophils in MDS was significantly higher than that in AML, and furthermore, the neutrophils in MDS more commonly contain t(8;21) than in AML. Our findings support the rationale for the WHO classification, and future studies on large patient populations should help clarify whether the spontaneous differentiation potential could be actively associated with a hematological manifestation of t(8;21) leukemias.

KW - Acute myeloid leukemia

KW - Fluorescence in situ hybridization analysis

KW - Myelodysplastic syndrome

KW - Oligoblastic leukemia

KW - Translocation (8;21)

UR - http://www.scopus.com/inward/record.url?scp=18744410919&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=18744410919&partnerID=8YFLogxK

U2 - 10.1034/j.1600-0609.2002.02770.x

DO - 10.1034/j.1600-0609.2002.02770.x

M3 - Article

C2 - 12406010

AN - SCOPUS:18744410919

VL - 69

SP - 165

EP - 170

JO - European Journal of Haematology

JF - European Journal of Haematology

SN - 0902-4441

IS - 3

ER -